News
Investment legend Warren Buffett has advocated for concentrated investing and there are both pros and cons to this approach.
Ares Capital (ARCC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Ares Capital's lower exposure to floating-rate debt and meaningful equity investments help stabilize income despite falling ...
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new ...
DIVIDENDS - Benefits of Dividend Investing in a volatile market environment. Our dividend strategy is tailored for our income ...
We came across a bullish thesis on Integral Ad Science Holding Corp. on P14 Capital’s site. In this article, we will ...
2h
The Business & Financial Times on MSNUnderstanding spin-offs: Why MTN should spin off its mobile money businessA spin-off is a type of corporate action where a company creates a new, independent entity by separating a part of its ...
Financing Secured via $4.5 Million Convertible Note Priced at a Premium to Market, Reflecting Investor Confidence in Future Growth ~ ...
17h
Livewire Markets on MSNThe top 10 Aussie equity funds delivered north of 20% last FY (the best nearly doubled it)In this wire, we crunch the data on the country's top-performing Aussie equities funds for FY25 and examine their positioning ...
4h
Zacks Investment Research on MSNIs Pagaya Stock's Low Valuation an Opportunity or a Value Trap?At a glance, Pagaya Technologies PGY stock looks attractively priced in terms of its price/sales (P/S) ratio when compared with its peers. Value investors try to find stocks that are either flying ...
9h
Zacks Investment Research on MSNShould You Invest in the SPDR S&P Capital Markets ETF (KCE)?Designed to provide broad exposure to the Financials - Brokers/ Capital markets segment of the equity market, the SPDR S&P Capital Markets ETF (KCE) is a passively managed exchange traded fund ...
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results